Oncology Pipeline & Trials
Oncology Pipeline Snapshot as of January 30, 2018
- Discovery Projects
-
12Phase 1
-
5Phase 2
-
19Phase 3
-
3Registration
- Total39
|
Compound Name |
Indication |
Phase |
Submission Type |
Compound Type |
|---|---|---|---|---|
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 2
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health Mechanism of Action:
Anti PD-L1 Inhibitor |
1st Line Merkel Cell Carcinoma (E.U.), Combo w/ PF-04518600 (OX40) for: Squamous Cell Carcinoma of the Head and Neck, Combo w/ PF-05082566 (4-1BB) for: Melanoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Triple-Negative Breast Cancer, *Combo w/ PF-04518600 (OX40) and PF-05082566 (4-1BB) for: Cancer, * Combo w/ talazoparib (MDV3800) for: Solid Tumors, *Cancer (Biologic) | Phase 2 | New Molecular Entity | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health Mechanism of Action:
Anti PD-L1 Inhibitor |
2nd Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health Mechanism of Action:
Anti PD-L1 Inhibitor |
1st Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health Mechanism of Action:
Anti PD-L1 Inhibitor |
1st Line Gastric Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health Mechanism of Action:
Anti PD-L1 Inhibitor |
Platinum Resistant/Refractory Ovarian Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health Mechanism of Action:
Anti PD-L1 Inhibitor |
1st Line Ovarian Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health Mechanism of Action:
Anti PD-L1 Inhibitor |
1st Line Urothelial Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health Mechanism of Action:
Anti PD-L1 Inhibitor |
1st Line Renal Cell Carcinoma (Biologic) (Combo w/ Inlyta (axitinib)) (BREAKTHROUGH) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health Mechanism of Action:
Anti PD-L1 Inhibitor |
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Bosulif (bosutinib)
Therapeutic Area:
Oncology Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health Mechanism of Action:
Abl and src-family Kinase Inhibitor |
1st Line Chronic Myelogenous Leukemia (E.U.) (ORPHAN - E.U.) | Registration | Product Enhancement | Small Molecule |
|
dacomitinib (PF-00299804)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health Mechanism of Action:
pan-HER Inhibitor |
1st Line EGFR-activating mutant Non-Small Cell Lung Cancer (ORPHAN - U.S.) | Phase 3 | New Molecular Entity | Small Molecule |
|
gedatolisib (PF-05212384)
Therapeutic Area:
Oncology Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health Mechanism of Action:
Phosphatidyl inositol-3 kinase catalytic sub-unit a inhibitor / mammalian target of rapamycin inhibitor (PI3K/mTOR) |
Cancer | Phase 1 | New Molecular Entity | Small Molecule |
|
glasdegib (PF-04449913)
Therapeutic Area:
Oncology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health Mechanism of Action:
SMO (smoothened) antagonist |
Acute Myeloid Leukemia (ORPHAN - U.S., E.U.), *Cancer | Phase 2 | New Molecular Entity | Small Molecule |
|
Ibrance (palbociclib)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health Mechanism of Action:
CDK 4,6 Kinase Inhibitor |
High Risk Early Breast Cancer | Phase 3 | Product Enhancement | Small Molecule |
|
Ibrance (palbociclib)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health Mechanism of Action:
CDK 4,6 Kinase Inhibitor |
Early Breast Cancer in Adjuvant Setting, *Cancer | Phase 3 | Product Enhancement | Small Molecule |
|
Ibrance (palbociclib)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health Mechanism of Action:
CDK 4,6 Kinase Inhibitor |
HER2+ Breast Cancer | Phase 3 | Product Enhancement | Small Molecule |
|
Inlyta (axitinib)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health Mechanism of Action:
VEGF Tyrosine Kinase Inhibitor |
Renal Cell Carcinoma Adjuvant, *Cancer combo w/ Merck's Keytruda (PD-1, pembrolizumab) | Phase 3 | Product Enhancement | Small Molecule |
|
lorlatinib (PF-06463922)
Therapeutic Area:
Oncology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health Mechanism of Action:
ALK Inhibitor |
2nd Line ALK Non-Small Cell Lung Cancer (BREAKTHROUGH, ORPHAN - U.S.) | Phase 2 | New Molecular Entity | Small Molecule |
